Texas Man Charged After Fatal Tesla Full Self-Driving Crash in Katy 
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust 
Tesla Q2 Deliveries Lift Chinese Auto Suppliers as EV Demand Improves 
Meta Cloud Ambitions Could Challenge AWS, Azure, and Google Cloud, Says Morgan Stanley 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
Chinese Copper Foil Maker Londian Files U.S. IPO as EV Battery Demand Grows 
Super Micro Employees Detained in Taiwan AI Server Export Investigation 
BHP Workers Approve New Labour Agreement at WA Iron Ore Operations 
Suncorp Cuts 2026 Premium Growth Forecast as Australia, New Zealand Markets Weaken 
Trump Administration to Launch Voluntary AI Standards for Frontier Models 
Samsung to Invest $90 Billion in South Korea to Expand AI Chip, Display, and Battery Production 
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
DOJ Seeks Dismissal of Fraud Charges Against Gautam Adani in U.S. Court 
Kioxia Bets on AI Memory Boom With Next-Gen NAND Production in Japan 
Lockheed Martin Emerges as Frontrunner to Acquire Ultra Maritime in $3.5 Billion Defense Deal 
Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round 
Bristol Myers Squibb Co would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments and shield itself from competition posed by Merck & Co’s Keytruda on its for its cancer immunotherapy, Opdivo.
The deal gives Bristol Myers, which acquired pharmaceutical company Celgene last year for $74 billion, access to Myokardia’s lead heart drug candidate with blockbuster potential, mavacamten.
According to David Nierengarten, a Wedbush analyst, mavacamten is expected to be a “multi-billion dollar asset” as sales estimates for the treatment of obstructive hypertrophic cardiomyopathy (HCM) is expected to reach about $2.5 billion by 2026.
Hypertrophic cardiomyopathy is estimated to affect one in every 500 people globally.
MyoKardia expects to submit a marketing application to the US health regulator for mavacamten as an obstructive HCM treatment in the first quarter of 2021.
Bristol Myers' portfolio of heart drugs includes blood thinner Eliquis, which made up about 21 percent of the company’s total sales in its latest reported quarter.
